Iparomlimab/Tuvonralimab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Iparomlimab/Tuvonralimab, covering 2026-03-06 to 2026-03-06. Get the full timeline:
Most recent: Clinical Trial Update: Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer [Phase 2]